Capillary Biomedical, headquartered in Irvine, California, develops the SteadiSet infusion set powered by its SteadiFlow technology to simplify and improve insulin pump therapy for people with Type 1 diabetes. The SteadiFlow platform features a soft, flexible cannula with multiple holes to reduce kinking, tissue damage, and inflammation, plus an integrated one-handed inserter. The SteadiSet is designed with materials selected for insulin stability and an adhesive optimized for extended wear to increase comfort, reliability, and predictability of insulin absorption. CapBio is pursuing extended-wear use of infusion sets for seven days and beyond and is conducting clinical studies to validate that performance. The company’s core cannula technology was developed with Professor Jeffrey Joseph and supported by the NIH and the JDRF T1D Fund. CapBio has previously raised over $10 million from organized angel investment groups and is advancing clinical trials to support broader adoption. Capillary Biomedical is developing the SteadiSet infusion set featuring SteadiFlow technology, a patented helical cannula design and a patent-pending helical inserter intended to reduce infusion set failures and insulin absorption variability. The company says the design is kink‑proof and combines advantages of steel needles and Teflon cannulas to improve comfort and reliability for pump users. Research specific to SteadiFlow was presented at the American Diabetes Association Scientific Sessions, and the core cannula work was developed at the Jefferson Artificial Pancreas Center with NIH and JDRF grant support. CapBio has assembled a veteran diabetes‑technology team, developed a minimal viable product, and filed multiple patent applications. Headquarters are in Irvine, California. The company plans clinical studies to support an initial 510(k) filing and preparation for a commercial launch in 2019; funds from the recent financing will support those activities.

Total raised

$4M

Funding rounds

2

Latest round

Seed

Latest activity

Aug 2018